A new gene therapy, utilizing the gene-editing tool known as CRISPR to treat sickle-cell disease, has received approval in the U.K., the U.S., and the EU. This milestone marks a potential breakthrough in alleviating the severe and life-threatening symptoms of sickle-cell disease while respecting ethical boundaries.
That’s not the only milestone that has been reached; it is also the first time that a therapy using CRISPR has been approved for the treatment of a condition in humans.
